Cord Blood Transplantation for Nonmalignant Disorders: Early Functional Immunity and High Survival

The authors evaluated the two-year Overall Survival after umbilical cord blood transplantation in patients with non-malignant disorders enrolled on a prospective clinical trial using either 5/6 or 6/6 umbilical cord blood as cell source.
[Blood Advances]

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News